Openbookopenbook
Equity
Formycon AG(0W4N)
EUR --+0.00%
Reward41Moderate
Risk47Moderate
📊75%Data
Thin -145% profit margin · Revenue down 13% YoY
0W4N
+0.0 · +0.00%
EUR · LSE
Formycon AG |
Earnings Deterioration
Market Cap:149.96M
ℹ️
Reward Rating
41
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
47
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0W4N to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Formycon AG?

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N · Verdict

Moderate reward · moderate risk

0W4N stands out on balance sheet and valuation, but watch the profitability signal.

Based on 88% data coverage

0W4N · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet73/100

    Current ratio 2.33

  • Valuation67/100

    Above average

  • Volatility65/100

    Above average

Watchouts 3

  • Profitability9/100

    -145% net margin · -15% ROE

  • Cash flow26/100

    -99% free-cash-flow margin

  • Growth43/100

    Revenue +1.5% CAGR

Model-based scoring. For information only — not financial advice.

What is Formycon AG?

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company is listed on the LSE in UK, with a market capitalisation of 149.96M.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap149.96M
P/E RatioN/A
Dividend YieldN/A
52 Week High31.3
52 Week Low15.9
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding9M
No. of Employees250
IndustryN/A
ExchangeLSE
Beta0.672
CurrencyEUR
Websitewww.formycon.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.